Abstract
Abstract
Stenotrophomonas maltophilia and Achromobacter xylosoxidans are emerging nosocomial, non-glucose fermenting, Gram-negative pathogens. In this nested case-control trial, independent predictors for S. maltophilia infections were hemodialysis and recent antibiotic usage (overall), while recent usage of fluoroquinolones, was independently associated with A. xylosoxidans infections. Infections were independently associated with multiple worse outcomes.
Publisher
Cambridge University Press (CUP)
Subject
Infectious Diseases,Microbiology (medical),Epidemiology
Reference12 articles.
1. Achromobacter xylosoxidans bacteremia: clinical and microbiological features in a 10-year case series;Perez Barragan;Rev Esp Quimioter,2018
2. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis;Paul;Antimicrob Agents Chemother,2010
3. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen;Brooke;Clin Microbiol Rev,2012
4. 1. WHO. WHO publishes list of bacteria for which new antibiotics are urgently needed, 2017. http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/. Accessed 13 August 2017.
5. Stenotrophomonas maltophilia phenotypic and genotypic features through 4-year cystic fibrosis lung colonization;Alcaraz;J Med Microbiol,2021